SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-05-15
Accession Number: 0001213900-26-057939
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390026057939/ea0290954-s1_synergy.htm

Chunk 6 of 16
Word Count: 1481
Character Count: 9224

Document Content:

stock. Nasdaq Capital Market Symbol SNYR Transfer Agent and Registrar VStock Transfer, LLC As of May 14, 2026, 15,079,956 shares of our common stock were issued and 14,899,883 shares were outstanding. Unless we indicate otherwise or the context otherwise requires, all information in this prospectus: ● does not reflect 1,540,000 Warrant Shares issuable upon the exercise of the Warrant at an exercise price of $0.01 per share; ● does not reflect 1,200,000 shares of common stock issuable upon the exercise of outstanding options at a weighted average exercise price of $2.38 per share; ● does not reflect 2,252,102 shares of common stock reserved for future issuance pursuant to the Synergy CHC Corp. 2024 Equity Incentive Plan (the “2024 Equity Incentive Plan”); and ● does not reflect 3,156,000 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $0.43 per share. RISK FACTORS

Investing in our securities
involves risk. Before making an investment decision, you should carefully consider the following discussion of risks and uncertainties
affecting us and our securities, together with all of the other information included or incorporated by reference in this prospectus,
including the consolidated financial statements and the accompanying notes and matters addressed in the section titled “Cautionary
Note Regarding Forward-Looking Statements,” in evaluating an investment in our securities. You should also consider the
risks, uncertainties and assumptions discussed under Item 1A, “Risk Factors,” in our most recent Annual Report
on Form 10-K, which is incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other
reports we file with the SEC in the future. The following risk factors apply to the business and operations of the Company and its consolidated
subsidiaries. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with
other events or circumstances, may have an adverse effect on our business, cash flows, financial condition and results of operations.
The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. The risks
and uncertainties we discuss in this prospectus and under similar headings in the documents incorporated by reference into this prospectus
are those that we currently believe may materially affect our company. Additional risks and uncertainties not presently known to us or
that we currently deem immaterial also may materially and adversely affect our business, financial condition and results of operations.
Past performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results
or trends in future periods. See also the section of this prospectus titled “Where You Can Find More Information.”

The risk factors set forth
below supplement the risk factors previously disclosed and should be read together with the risk factors incorporated by reference herein
and any additional risk factors that we may include in subsequent periodic filings with the SEC.

Risks Related to this Offering and Our Common
Stock

It is not possible to predict the actual
number of shares we will issue to the Selling Stockholder.

The purchase price to be paid
by the Selling Stockholder for the ELOC Shares will be the lesser of (i) ninety-five percent (95%) of the average of the three lowest
traded prices of the Company’s common stock during the five trading days immediately preceding the date of the Put Notice (as defined
in the ELOC Purchase Agreement) and (ii) ninety-five percent (95%) of the lowest closing price of the Company’s common stock on
any trading day during the three trading days immediately following the Clearing Date (as defined in the ELOC Purchase Agreement). The
Company shall, in its sole discretion, select the amount of ELOC Shares requested by the Company in each Put Notice. However, such amount
must not be less than $25,000 and may not exceed the lesser of (i) $2,500,000 or (ii) 200% of the average daily trading volume of the
common stock during the three trading days immediately before the date of the Put Notice. Accordingly, the number of ELOC Shares issuable
pursuant to the ELOC Purchase Agreement cannot be determined at this time and may change over time.

Investors who buy shares at different times
will likely pay different prices.

The Selling Stockholder will
purchase shares in this offering at different times and, therefore, will likely pay different prices. As such, investors may experience
different levels of dilution and different outcomes in their investment results. The Selling Stockholder may sell such shares at different
times and at different prices. Investors may experience a decline in the value of the shares they purchase from the Selling Stockholder
in this offering as a result of sales made by us in future transactions to the Selling Stockholder at prices lower than the prices they
paid.

The issuance of common stock to the Selling
Stockholder may cause substantial dilution to our existing stockholders and the sale of such shares acquired by the Selling Stockholder
could cause the price of our common stock to decline.

We are registering for resale
by the Selling Stockholder up to 101,710,000 shares of common stock, comprised of (i) 100,000,000 ELOC Shares, (ii) 1,540,000 Warrant
Shares and 170,000 Existing Shares. The number of shares of our common stock ultimately offered for resale by the Selling Stockholder
under this prospectus is dependent upon the number of ELOC Shares issued. Depending on a variety of factors, including market liquidity
of our common stock, the issuance of shares to the Selling Stockholder may cause the trading price of our common stock to decline.

We have not historically paid or declared
any dividends on our common stock and do not expect to pay or declare cash dividends in the future on a regular basis, if at all.

We have not historically paid
or declared any dividends on our common stock. Any future dividends on our common stock will be declared at the discretion of our board
of directors and will depend, among other things, on our earnings, our financial requirements for future operations and growth, and other
facts as we may then deem appropriate. As such, the return on your investment, if any, has historically been dependent solely on an increase,
if any, in the market value of our common stock.

USE OF PROCEEDS

The Selling Stockholder will
receive all of the proceeds of the sale of shares of common stock offered from time to time pursuant to this prospectus. Accordingly,
we will not receive any proceeds from the sale of shares of common stock that may be sold from time to time pursuant to this prospectus.

We may receive up to $36,000,000
in aggregate gross proceeds under the ELOC Purchase Agreement in connection with sales of our shares of common stock to the Selling Stockholder
that we may, in our discretion, elect to make, from time to time pursuant to the ELOC Purchase Agreement after the date of this prospectus.
As of the date of this prospectus, we cannot currently allocate specific percentages of the proceeds that we may obtain under the ELOC
Purchase Agreement to particular uses and we cannot estimate the amount of proceeds that we will actually spend as opposed to retaining
for working capital purposes. Therefore, we currently intend to use the net proceeds received under the ELOC Purchase Agreement for working
capital and general corporate purposes.

The amounts and timing of our
actual expenditures will depend upon numerous factors, including our sales and marketing efforts, demand for our products, our operating
costs and the other factors described under and incorporated by reference in “Risk Factors” in this prospectus.

Our expected use of net proceeds
from the sale of our shares of common stock under the ELOC Purchase Agreement represents our current intentions based upon our present
plans and business condition, which could change in the future as our plans and business conditions evolve. Circumstances that may give
rise to a change in the use of proceeds and the alternate purposes for which the proceeds may be used include:

●	The existence of other opportunities or the need to take
advantage of changes in timing of our existing activities;

●	The need or desire on our part to accelerate, increase or
eliminate existing initiatives due to, among other things, changing market conditions and competitive developments; and/or

●	If strategic opportunities present themselves (including
acquisitions, joint ventures, licensing and other similar transactions).

As a result, we cannot predict
with any certainty our use of the net proceeds from this offering. Our management will retain broad discretion over the allocation of
the net proceeds from this offering. Accordingly, we will have discretion in the application of the net proceeds, and investors will be
relying on our judgment regarding the application of the proceeds we may receive under the ELOC Purchase Agreement.

SELLING STOCKHOLDER